drugset

drugset / Trial / NCT00116909

A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line Therapy

NCT00116909 ↗

Phase 2 Completed 85 enrolled OSI Pharmaceuticals

Treatment

Summary

Multi-center, Phase II study to evaluate the efficacy and safety of OSI-7904Lin head and neck cancer in patients who have failed first-line therapy

Timeline

Start: 2004-08
Primary completion: —
Completion: 2005-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	OSI-7904	Small molecule	—	—

Indications